雷帕鸣治疗效果怎么样？

It is suitable for patients aged 13 or above who have received kidney transplants to prevent organ rejection. Recommended for use in combination with cyclosporine and corticosteroids. What is the therapeutic effect of Rapamin? Let's take a look now.

Rapamin inhibits the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukins IL-2, IL-4 and IL-15). It also inhibits the production of antibodies. In cells, rapamycin binds to the immunophilin, FK-binding protein-12 (FKBP-12), to generate the FKBP-12 immunosuppressive complex. This complex binds to the mammalian rapamycin BA molecule (mTOR, a key regulatory kinase) and inhibits its activity, thereby inhibiting the progression from G1 to S phase in the cell cycle.

Trial 1 was conducted at 38 research sites in the United States, with 719 patients participating. Randomly assigned after transplantation: 284 patients received rapamine 2 mg/day, 274 patients received rapamine 5 mg/day, and 161 patients received azathioprine 2-3 mg/kg/day.

Trial 2 was conducted at 34 research units in Australia, Canada, Europe and the United States, with 576 patients participating. Randomly assigned before transplantation: 227 patients received rapamin 2 mg/day, 219 patients received rapamin 5 mg/day, and 130 patients received placebo. In both trials, antilymphocyte antibody induction therapy was contraindicated. In both trials, the primary efficacy endpoint was the rate of treatment failure within the first 6 months after transplantation. Treatment failure was defined as the first episode of acute rejection (confirmed by biopsy), graft loss, or death. Trial analysis results: Compared with azathioprine and placebo, rapamycin at 2 mg/day and 5 mg/day dose levels significantly reduced the incidence of treatment failure 6 months after transplantation.

The above are the therapeutic effects provided by Medical Companion Travel. If you have other questions about medication, please consult Medical Companion Travel.